C-peptide vs Dulaglutide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Dulaglutide |
|---|---|---|
| Category | Pain Management | Weight Management |
| Full Name | Connecting peptide (C-peptide) | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | 3020.3 Da | ~63,000 Da |
| Half-Life | ~20-30 min | About 5 days |
| Amino Acids | 31 | N/A |
| Typical Dose | no approved analgesic dose|research-only | 0.75-4.5 mg weekly |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 700 |
| Research Status | Pre-clinical | Approved |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.